Candidate-Allergen Testing in 4,654 Spanish Registry Patients

November 11, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What can this study tell workers, families and occupational-health teams—and what would go beyond the evidence? This review keeps every number attached to its population, denominator, comparator and timepoint.

Study snapshot

Study element	Reported detail
Population	4,654 consecutive Spanish registry patients tested with diazolidinyl urea, imidazolidinyl urea and bronopol; 1,890 of them were tested with the other candidate allergens.
Design	Prospective observational multicenter registry study conducted in 2019 and 2020.
Comparator	Candidate allergens were compared on sensitization and current-relevance rates within the tested groups.
Timepoint	Patch testing during 2019–2020; no longitudinal outcome follow-up.
Key result	Seven candidate allergens had sensitization rates above 1%. Linalool hydroperoxide, HEMA and limonene hydroperoxide each had a current-relevance rate above 1%; benzisothiazolinone and textile dye mix were between 0.9% and 1%.
Funding/conflict context	No grant or conflict-of-interest statement appears in the PubMed record retrieved for this review.

What was actually measured?

Seven candidate allergens had sensitization rates above 1%. Linalool hydroperoxide, HEMA and limonene hydroperoxide each had a current-relevance rate above 1%; benzisothiazolinone and textile dye mix were between 0.9% and 1%.

The two denominators matter because not every patient received every candidate allergen. Prospective consecutive registry capture supports comparison of what might add value to a baseline series.

The denominator defines the scope. A patch-test clinic, selected case series, compensation registry, online questionnaire, workplace cohort and general-population survey answer different questions. A percentage from one cannot be silently transferred to the others.

What the result does not prove

Patch-test referral data are not general-population prevalence data. Testing coverage differed by allergen, and relevance judgments can vary across centers.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting practices, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors' conclusions, this interpretation or any product.

Exposure detail matters more than the job label

Workers with the same title can handle different materials for different durations. Useful documentation identifies the exact product or process, the route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, a clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None of those steps alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, metal, resin, cleanser, food, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve on days away or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredient information and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes